Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

Nilotinib is a potent selective inhibitor of the BCR-ABL tyrosine kinase approved for use in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP), and in CML-CP and CML-accelerated phase after imatinib failure. Nilotinib (400 mg twice daily) was approved on the basis of t...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Blood
Glavni autori: Kantarjian, Hagop M., Giles, Francis J., Bhalla, Kapil N., Pinilla-Ibarz, Javier, Larson, Richard A., Gattermann, Norbert, Ottmann, Oliver G., Hochhaus, Andreas, Radich, Jerald P., Saglio, Giuseppe, Hughes, Timothy P., Martinelli, Giovanni, Kim, Dong-Wook, Shou, Yaping, Gallagher, Neil J., Blakesley, Rick, Baccarani, Michele, Cortes, Jorge, le Coutre, Philipp D.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2011
Teme:
Clinical Trials and Observations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4916554/
https://ncbi.nlm.nih.gov/pubmed/21098399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-03-277152
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items